Results 181 to 190 of about 149,982 (260)

Adjuvant Radiotherapy in pT1-2N0M0 Head and Neck Adenoid Cystic Carcinoma. [PDF]

Laryngoscope
Kaki PC, Patel AM, Haleem A, Patel AR, Bahethi R, Wassef DW, Cowan PT, Park RCW.   +7 more
europepmc   +1 more source

The effect of adjuvant radiotherapy on M0 adenoid cystic carcinoma of the breast: a retrospective cohort study based on SEER data. [PDF]

Gland Surg
Chen H, Long Y, Luo Z, Li W, Zhang Y.
europepmc   +1 more source

Survival Benefit of Adjuvant Radiotherapy After Surgery in Patients With T1-2N1M0 Hypopharyngeal Squamous Cell Carcinoma: A Dual-Cohort Analysis of SEER and Institutional Data. [PDF]

Cancer Med
Hu Z, Ma R, Wen Y, Deng J, Sun W, Chen L, Chen S, Wen W, Lei W.   +8 more
europepmc   +1 more source

Perineural and Lymphovascular Invasion in Resected Pancreatic Ductal Adenocarcinoma: A High-Risk Subgroup That Could Benefit from Adjuvant Radiotherapy. [PDF]

J Clin Med
Gümüş T, Özkılıç A, Temel R, Nart D, Yılmaz F, Karabulut B, Uğuz A.   +6 more
europepmc   +1 more source

Is there an impact of autoimmune rheumatological diseases on cutaneous toxicity in breast cancer adjuvant radiotherapy? A mono-institutional experience. [PDF]

Breast Cancer
de Pasquale G, Donatiello V, Lucarelli M, Bonelli R, Di Nicola M, Porreca A, Vinciguerra A, Nuzzo M, Rosa C, D'Aviero A, Genovesi D.   +10 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Dosimetric Effect of Thymus on Radiation-Induced Lymphopenia in Breast Cancer Patients Who Received Adjuvant Radiotherapy. [PDF]

Dose Response
Xia T, Zheng S, Qian J, Yang Y, Jin L, Jiang G, Zhao P, Hu Y, Li S, Zhang L, Tian Y, Cai S.   +11 more
europepmc   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

BMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li, Honglin Huang, Qianyi Zeng, Li Zeng, Ziman Yang, Jinyang Shen, Shun Li, Hong Yang, Yiyao Liu, Chunhui Wu   +9 more
wiley   +1 more source

Timing of adjuvant radiotherapy for early-stage endometrial carcinoma: a single-center retrospective cohort study. [PDF]

J Gynecol Oncol
Yan Z, Wang W, Jiao S, Ren K, Hou X, Hu K, Zhang F.   +6 more
europepmc   +1 more source